Johnson & Johnson (JNJ)

$227.25 -0.04 (-0.02%)
Market Cap 547.51B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.05
Forward PE 19.70
Profit Margin 28.46%
Debt to Equity Ratio 0.50
Volume 11,045,500
Avg Vol 9,122,992
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 86%
Beta 0.34
Analysts Strong Sell
Price Target $231.44

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Night_Owl_Biotech
Night_Owl_Biotech Jan. 31 at 4:21 PM
Attached is the written transcript from the J&J Q425 earnings call where a $JNJ analyst asked about the consequence of J&J's new combo therapy in RRMM (posted at ASH) versus Carvykti from $LEGN or better said hoping to understand what impact will it have on Carvykti sales We have no clinical expertise & can only guess as to how to read the answers. As we interpret, the J&J executive does not provide a direct answer. She only boasts about having therapies for all 2L & 3L RRMM patients...but again does not provide guidance on Carvykti's placement We do note she alluded to a 70/30 split. If anyone can provide a data driven answer it would be appreciated. $XBI $IBB $NBI @Tigerpicko @2malcontent @outlawinvestor1 @Georgeson @DiamondHandsBTW
1 · Reply
3DBuilds
3DBuilds Jan. 31 at 5:13 AM
$BEAM $BMY $JNJ $NTLA $REGN
0 · Reply
TradeTracs
TradeTracs Jan. 30 at 5:53 PM
Brands Americans Trust Most in 2026 🛡️ In a time when reliability and value matter most, everyday giants outshine flashy global brands. YouGov's latest survey reveals the winners,brands that consumers count on for trust and consistency. Top of the list: Amazon (AMZN) – 54.5 Band-Aid (JNJ) – 53.0 Dawn (PG) – 51.7 Dove (UL) – 48.5 Samsung (SSNLF) – 47.9 These names aren't just familiar; they're trusted. People are leaning into brands that deliver dependability, not buzz. Are your favorites on the list? Follow for insights on what consumers really value. $AMZN $JNJ $PG $UL $SSNLF
0 · Reply
Investor6
Investor6 Jan. 30 at 4:21 PM
$JNJ Johnson & Johnson announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed an additional indication for its prostate cancer therapy Akeega, marketed with $GSK (GSK).
0 · Reply
LiveSquawk
LiveSquawk Jan. 30 at 3:08 PM
$JNJ | Johnson & Johnson Receives CHMP Positive Opinion For AKEEGA For The Treatment Of Patients With Metastatic Hormone-Sensitive Prostate Cancer With BRCA1/2 Mutations https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-chmp-positive-opinion-for-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc-with-brca1-2-mutations
0 · Reply
frb1985
frb1985 Jan. 30 at 2:53 PM
$JNJ
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 2:10 PM
$PMN fast track designation and DSMB approval and with this news $175 MILLION in the pocket ready to fly 🛫🚀 https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $CELG $JNJ $PFE
0 · Reply
Let_us_Rocket
Let_us_Rocket Jan. 30 at 1:19 PM
$SENS $DXCM $ABT $JNJ If you want your money back in the diabetes sector, come to $NVO Super bullish market launch, far above all estimated sales expectations — the new pill is already exploding, and the stock looks next in line 🚀🔥
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 30 at 1:13 PM
$JNJ
0 · Reply
Suite510
Suite510 Jan. 30 at 12:31 PM
$JNJ $KVUE A lot of pissed off woman out there Filed by five cancer victims suing J&J over its talc products, the lawsuit alleged that the bankruptcy strategy was designed to put billions of dollars out of plaintiffs' reach in order to "hinder, delay, and defraud these women and prevent them from ever having their day in court."
0 · Reply
Latest News on JNJ
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 2:43 PM EST - 1 day ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 30, 2026, 7:19 AM EST - 1 day ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 6:32 PM EST - 2 days ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

Jan 29, 2026, 12:42 PM EST - 2 days ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 28, 2026, 9:38 AM EST - 3 days ago

Johnson & Johnson: Strong Momentum Heading Into 2026

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 3:49 PM EST - 4 days ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 27, 2026, 8:00 AM EST - 4 days ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 6 days ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 22, 2026, 12:15 AM EST - 10 days ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 11:20 PM EST - 10 days ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 6:45 PM EST - 10 days ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 1:56 PM EST - 10 days ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 12:15 PM EST - 10 days ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

Jan 21, 2026, 10:00 AM EST - 10 days ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 7:26 AM EST - 10 days ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:23 AM EST - 10 days ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 10 days ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 6:20 AM EST - 10 days ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 21, 2026, 1:07 AM EST - 11 days ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 20, 2026, 8:37 AM EST - 11 days ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 8:00 AM EST - 12 days ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

Jan 19, 2026, 5:08 AM EST - 12 days ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 14, 2026, 4:30 PM EST - 17 days ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 8:00 AM EST - 18 days ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

Jan 13, 2026, 2:40 AM EST - 18 days ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 6:32 PM EST - 19 days ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:06 PM EST - 19 days ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 20 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 10:00 AM EST - 21 days ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

Jan 10, 2026, 9:52 AM EST - 21 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 9:59 AM EST - 22 days ago

Cramer's Mad Dash: Johnson & Johnson

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 9, 2026, 5:10 AM EST - 22 days ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 23 days ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:43 PM EST - 23 days ago

Johnson & Johnson reaches deal with US government to lower drug prices

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 8, 2026, 8:24 PM EST - 23 days ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 7, 2026, 8:00 AM EST - 24 days ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Jan 6, 2026, 8:03 AM EST - 25 days ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 6, 2026, 6:52 AM EST - 25 days ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

Jan 2, 2026, 5:06 PM EST - 4 weeks ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

Jan 2, 2026, 4:17 PM EST - 4 weeks ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Jan 2, 2026, 8:00 AM EST - 4 weeks ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 4 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

The Big 3: JNJ, SNDK, TWLO

Dec 30, 2025, 1:31 PM EST - 4 weeks ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 9:55 AM EST - 4 weeks ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

PG

More Upside For JNJ Stock In 2026?

Dec 30, 2025, 5:05 AM EST - 4 weeks ago

More Upside For JNJ Stock In 2026?

Dogs of the Dow Had a Strong Year as Dividends Paid Off

Dec 29, 2025, 1:56 PM EST - 4 weeks ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 29, 2025, 8:00 AM EST - 4 weeks ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 4 weeks ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 26, 2025, 8:13 AM EST - 5 weeks ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 11:41 AM EST - 5 weeks ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Night_Owl_Biotech
Night_Owl_Biotech Jan. 31 at 4:21 PM
Attached is the written transcript from the J&J Q425 earnings call where a $JNJ analyst asked about the consequence of J&J's new combo therapy in RRMM (posted at ASH) versus Carvykti from $LEGN or better said hoping to understand what impact will it have on Carvykti sales We have no clinical expertise & can only guess as to how to read the answers. As we interpret, the J&J executive does not provide a direct answer. She only boasts about having therapies for all 2L & 3L RRMM patients...but again does not provide guidance on Carvykti's placement We do note she alluded to a 70/30 split. If anyone can provide a data driven answer it would be appreciated. $XBI $IBB $NBI @Tigerpicko @2malcontent @outlawinvestor1 @Georgeson @DiamondHandsBTW
1 · Reply
3DBuilds
3DBuilds Jan. 31 at 5:13 AM
$BEAM $BMY $JNJ $NTLA $REGN
0 · Reply
TradeTracs
TradeTracs Jan. 30 at 5:53 PM
Brands Americans Trust Most in 2026 🛡️ In a time when reliability and value matter most, everyday giants outshine flashy global brands. YouGov's latest survey reveals the winners,brands that consumers count on for trust and consistency. Top of the list: Amazon (AMZN) – 54.5 Band-Aid (JNJ) – 53.0 Dawn (PG) – 51.7 Dove (UL) – 48.5 Samsung (SSNLF) – 47.9 These names aren't just familiar; they're trusted. People are leaning into brands that deliver dependability, not buzz. Are your favorites on the list? Follow for insights on what consumers really value. $AMZN $JNJ $PG $UL $SSNLF
0 · Reply
Investor6
Investor6 Jan. 30 at 4:21 PM
$JNJ Johnson & Johnson announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed an additional indication for its prostate cancer therapy Akeega, marketed with $GSK (GSK).
0 · Reply
LiveSquawk
LiveSquawk Jan. 30 at 3:08 PM
$JNJ | Johnson & Johnson Receives CHMP Positive Opinion For AKEEGA For The Treatment Of Patients With Metastatic Hormone-Sensitive Prostate Cancer With BRCA1/2 Mutations https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-chmp-positive-opinion-for-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc-with-brca1-2-mutations
0 · Reply
frb1985
frb1985 Jan. 30 at 2:53 PM
$JNJ
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 2:10 PM
$PMN fast track designation and DSMB approval and with this news $175 MILLION in the pocket ready to fly 🛫🚀 https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $CELG $JNJ $PFE
0 · Reply
Let_us_Rocket
Let_us_Rocket Jan. 30 at 1:19 PM
$SENS $DXCM $ABT $JNJ If you want your money back in the diabetes sector, come to $NVO Super bullish market launch, far above all estimated sales expectations — the new pill is already exploding, and the stock looks next in line 🚀🔥
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 30 at 1:13 PM
$JNJ
0 · Reply
Suite510
Suite510 Jan. 30 at 12:31 PM
$JNJ $KVUE A lot of pissed off woman out there Filed by five cancer victims suing J&J over its talc products, the lawsuit alleged that the bankruptcy strategy was designed to put billions of dollars out of plaintiffs' reach in order to "hinder, delay, and defraud these women and prevent them from ever having their day in court."
0 · Reply
InItToWinIt100
InItToWinIt100 Jan. 29 at 10:48 PM
$SPY $XLV $JNJ Trump talking opiods. New Executive Order. https://www.youtube.com/watch?v=OE2NtBhozT4
0 · Reply
IN0V8
IN0V8 Jan. 29 at 4:34 PM
$JNJ 1/28/26 Morgan Stanley raises to overweight from equal-weight Morgan Stanley raises target price to $262.00 from $200.00
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 29 at 3:05 PM
$ABT $UNH $JNJ $ISRG $MDT From Abbott Laboratories (NYSE:ABT) to UnitedHealth Group (NYSE:UNH), and Johnson & Johnson (NYSE:JNJ), healthcare companies continue to benefit from non-discretionary demand, aging populations, and innovation-driven growth. https://biotechhealthx.com/biotech-news/heres-why-healthcare-equipment-and-services-keep-winning-even-when-markets-panic/
0 · Reply
Suite510
Suite510 Jan. 29 at 1:54 PM
$JNJ $KVUE hey how’s it going in here? 🤣 Just a matter of time now 💣 Expert Challenges by J&J Fail in Federal Talc Ovarian Cancer Wrongful Death and Personal Injury Cases
1 · Reply
clan
clan Jan. 29 at 12:43 PM
$ELTP In a couple weeks, when Elite reports qrt.-ended 12/31/25 results, it is going to BLOW AWAY Revenues for the same qrt., previous year!!! Heads will turn! $TEVA $JNJ
1 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 6:00 AM
$JNJ just beat Q4 — but the real question is whether this rally has legs. 👀 The company topped Q4 expectations and guided 2026 sales to $100–$101B, with Innovative Medicine and MedTech growth helping offset the Stelara LOE. A steady setup, but worth a closer look. Should you stay invested? Full breakdown here 👉 https://www.zacks.com/stock/news/2824501/should-you-stay-invested-in-jj-stock-after-q4-beat-solid-guidance?cid=sm-stocktwits-2-2824501-teaser-30688&ADID=SYND_STOCKTWITS_TWEET_2_2824501_TEASER_30688
0 · Reply
Quantumup
Quantumup Jan. 28 at 9:41 PM
Raymond James⬆️ $TYRA's PT to $55 from $35 and reiterated at Strong Buy. $URGN $JNJ $PFE $MRK ALPMY Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2016625267691683922?s=20
0 · Reply
clan
clan Jan. 28 at 6:53 PM
$JNJ $GILD $CIPLA.NSE Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No more shooting up at meals for diabetics!❤️
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 28 at 6:51 PM
$PDYN $UNH $ABBV $JNJ
0 · Reply
ZacksResearch
ZacksResearch Jan. 28 at 5:03 PM
$JNJ just beat Q4 — but the real question is whether this rally has legs. 👀 The company topped Q4 expectations and guided 2026 sales to $100–$101B, with Innovative Medicine and MedTech growth helping offset the Stelara LOE. A steady setup, but worth a closer look. Should you stay invested? Full breakdown here 👉 https://www.zacks.com/stock/news/2824501/should-you-stay-invested-in-jj-stock-after-q4-beat-solid-guidance?cid=sm-stocktwits-2-2824501-teaser-30688&ADID=SYND_STOCKTWITS_TWEET_2_2824501_TEASER_30688
0 · Reply
DavidFloydTrader
DavidFloydTrader Jan. 28 at 4:26 PM
We don’t take swing trades without market context. If equity indices aren’t aligned, individual stock setups don’t matter. In early January, they were. $JNJ qualified. Plan defined. Execution complete.
0 · Reply
3DBuilds
3DBuilds Jan. 28 at 4:04 PM
$NTLA $BEAM $JNJ $REGN $BMY The Future is here People 💯 💰 🌎
0 · Reply